PARP Inhibitor + Avastin Delays Cancer Progression When Used as Initial Treatment for Ovarian Cancer

(October 9, 2019)

Maintenance therapy with the PARP inhibitor Lynparza (olaparib) added to Avastin (bevacizumab) resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer  according to the... Continue Reading

E-Cigarette Smoke Causes Lung Cancer in Mice

(October 8, 2019)

Exposure to e-cigarette smoke caused mice to develop lung cancer, a new study finds. Published online October 7 in Proceedings of National Academy of Sciences (PNAS), the study found that 9 of 40 mice (22.5 percent) exposed to e-cigarette smoke with... Continue Reading

Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC

(October 4, 2019)

Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA... Continue Reading

Addition of Avastin to Tarceva Doesn’t Improve Outcome in EGF-Positive NSCLC

(September 27, 2019)

Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the... Continue Reading

Monitoring of Symptoms More Important Than Blood Counts in Polycythemia Vera

(September 24, 2019)

A recent study supports what individuals with polycythemia vera (PV) have known for years. PV associated symptoms are underappreciated by doctors and don’t necessarily correlate with blood counts levels. Individuals with PV can experience symptoms... Continue Reading

Ask the Expert About Treatment of Advanced Colon Cancer

(September 23, 2019)

Dr. Tanios Bekaii- Saab, MD, Program Head Mayo Clinic answered questions about management of advanced colo-rectal cancer CancerConnect and The Personalized Medicine Foundation were pleased to provide patients and caregivers the opportunity to ask questions... Continue Reading

Keytruda plus Lenvima Approved for Certain Patients with Uterine Cancer

(September 19, 2019)

The United States Food and Drug Administration (FDA) granted accelerated approval to the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability... Continue Reading

Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia

(September 3, 2019)

Flumatinib may be more effective than Gleevec (imatinib) for initial treatment of chronic phase-chronic myeloid leukemia (CML-CP) according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Chronic... Continue Reading

Isatuximab in Multiple Myeloma

(August 27, 2019)

The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to randomized phase 3 study results presented at ASCO Annual... Continue Reading

Lynparza-Avastin Maintenance Delays Progression of Ovarian Cancer

(August 20, 2019)

Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza (olaparib) plus Avastin (bevacizumab) compared to Avastin alone in women with or without BRCA gene mutations have been... Continue Reading

FDA Orders Allergan to Recall Textured Breast Implants Over Cancer Risk

(August 19, 2019)

The U.S. Food and Drug Administration (FDA) has requested that Allergan recall its BIOCELL textured breast implants due to a risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), according to an announcement from the agency. “Although... Continue Reading

Inherited pancreatic cancer risk mutation identified

(August 15, 2019)

Scientists have found a rare, inherited gene mutation that raises the risk of pancreatic cancer and other malignancies In the future, individuals with a strong family history of pancreatic cancer could be tested to determine if they carry the mutation. Scientists... Continue Reading

Next Page »